1 | high-risk | 8,704 |
2 | low-risk | 1,549 |
3 | at-risk | 1,143 |
4 | unselected | 865 |
5 | intermediate-risk | 269 |
6 | higher-risk | 186 |
7 | difficult-to-treat | 145 |
8 | lower-risk | 104 |
9 | average-risk | 90 |
10 | moderate-risk | 77 |
11 | poor-risk | 76 |
12 | standard-risk | 57 |
13 | poor-prognosis | 48 |
14 | non-renal | 46 |
15 | nontrial | 45 |
16 | ranibizumab-treated | 42 |
17 | all-comer | 40 |
18 | non-selected | 40 |
19 | well-selected | 39 |
20 | nonselected | 38 |
21 | non-trial | 35 |
22 | nontransplant | 35 |
23 | pci-treated | 32 |
24 | medium-risk | 31 |
25 | non-high-risk | 31 |
26 | good-risk | 30 |
27 | substance-using | 28 |
28 | pre-symptomatic | 26 |
29 | hard-to-reach | 25 |
30 | very-high-risk | 25 |
31 | non-art | 24 |
32 | low-weight | 23 |
33 | non-bleeding | 22 |
34 | chemotherapy-treated | 20 |
35 | non-fn | 20 |
36 | alloimmunized | 19 |
37 | no-option | 19 |
38 | nonventilated | 19 |
39 | ultra-early | 18 |
40 | out-of-treatment | 17 |
41 | non-breastfeeding | 16 |
42 | nonenrolled | 15 |
43 | rituximab-refractory | 15 |
44 | biomarker-negative | 14 |
45 | nonbleeding | 14 |
46 | nonuremic | 14 |
47 | uncured | 14 |
48 | ultra-high-risk | 13 |
49 | met-positive | 11 |
50 | mupirocin-treated | 11 |
51 | non-risk | 11 |
52 | b-infected | 10 |
53 | nonreperfused | 10 |
54 | risk-stratifying | 10 |
55 | well-treated | 10 |
56 | hard-to-treat | 9 |
57 | highrisk | 9 |
58 | non-ibd | 9 |
59 | nonsedated | 9 |
60 | 4237 | 8 |
61 | c-infected | 8 |
62 | difluprednate-treated | 8 |
63 | low-complexity | 8 |
64 | ptsd+ | 8 |
65 | secure-c | 8 |
66 | under-served | 8 |
67 | 2,627 | 7 |
68 | 3180 | 7 |
69 | conservatively-treated | 7 |
70 | fibrinolytic-treated | 7 |
71 | high-complexity | 7 |
72 | medication-treated | 7 |
73 | methotrexate-refractory | 7 |
74 | nonfluctuating | 7 |
75 | 2312 | 6 |
76 | 2706 | 6 |
77 | biomarker-defined | 6 |
78 | cancer-prone | 6 |
79 | fish-negative | 6 |
80 | good-grade | 6 |
81 | non-gca | 6 |
82 | non-young | 6 |
83 | platinum-pretreated | 6 |
84 | sitosterolemic | 6 |
85 | sodium-sensitive | 6 |
86 | tolvaptan-treated | 6 |
87 | 2,518 | 5 |
88 | 4718 | 5 |
89 | brca-mutated | 5 |
90 | doctor-shopping | 5 |
91 | esomeprazole-treated | 5 |
92 | genotype-negative | 5 |
93 | gord-negative | 5 |
94 | high-caries-risk | 5 |
95 | high-cvd-risk | 5 |
96 | high-intermediate-risk | 5 |
97 | high-need | 5 |
98 | high-surgical-risk | 5 |
99 | high-tension | 5 |
100 | hpv-naïve | 5 |
101 | jupiter-eligible | 5 |
102 | less-active | 5 |
103 | moderate/high-risk | 5 |
104 | mtx-resistant | 5 |
105 | non-16 | 5 |
106 | non-pneumonic | 5 |
107 | nonreferred | 5 |
108 | overnight-stay | 5 |
109 | polytraumatized | 5 |
110 | ppci-treated | 5 |
111 | remifentanil-treated | 5 |
112 | 2,036 | 4 |
113 | 2,974 | 4 |
114 | 2827 | 4 |
115 | 2984 | 4 |
116 | 4035 | 4 |
117 | 4282 | 4 |
118 | 8351 | 4 |
119 | adverse-risk | 4 |
120 | delayed-arm | 4 |
121 | gastric-cardia | 4 |
122 | gata-3-negative | 4 |
123 | high-coverage | 4 |
124 | highly-selected | 4 |
125 | in-tunnel | 4 |
126 | intensive-lifestyle | 4 |
127 | intermediate/high-risk | 4 |
128 | lavender-thymol-treated | 4 |
129 | lung-healthy | 4 |
130 | non-converted | 4 |
131 | non-pad | 4 |
132 | non-typical | 4 |
133 | nonintervened | 4 |
134 | out-trial | 4 |
135 | photon-treated | 4 |
136 | polymorbid | 4 |
137 | roxithromycin-treated | 4 |
138 | screening-eligible | 4 |
139 | three-member | 4 |
140 | wadam | 4 |
141 | well-infant | 4 |
142 | wide-type | 4 |
143 | β3t-positive | 4 |
144 | 14,090 | 3 |
145 | 14,776 | 3 |
146 | 25,104 | 3 |
147 | 3334 | 3 |
148 | 4,137 | 3 |
149 | 4,295 | 3 |
150 | 5,733 | 3 |
151 | 6,380 | 3 |
152 | acidilobus-like | 3 |
153 | acute-mi | 3 |
154 | added-risk | 3 |
155 | alcohol-responsive | 3 |
156 | anti-ccp-negative | 3 |
157 | any-type | 3 |
158 | cmv-antibody-negative | 3 |
159 | cns-negative | 3 |
160 | co-trimoxazole-treated | 3 |
161 | difficult-to-engage | 3 |
162 | dm1-affected | 3 |
163 | dually-diagnosed | 3 |
164 | ei-aed | 3 |
165 | er-negative/her2-negative | 3 |
166 | feeble-minded | 3 |
167 | general-risk | 3 |
168 | gerontal | 3 |
169 | gnrha-treated | 3 |
170 | gstt1-null | 3 |
171 | high-barriers | 3 |
172 | hm100 | 3 |
173 | home-bound | 3 |
174 | immunoresponsive | 3 |
175 | media-recruited | 3 |
176 | multi-problem | 3 |
177 | non-bloom | 3 |
178 | non-educated | 3 |
179 | non-hc2-targeted | 3 |
180 | non-low-risk | 3 |
181 | non-ptdm | 3 |
182 | non-sci | 3 |
183 | non-varus | 3 |
184 | poor-outcome | 3 |
185 | pre-orthodontic | 3 |
186 | selenium-replete | 3 |
187 | slow-progressing | 3 |
188 | stimulant-exposed | 3 |
189 | telavancin-treated | 3 |
190 | transplantation-eligible | 3 |
191 | vasc+ | 3 |
192 | vegfr-tki-refractory | 3 |
193 | vemurafenib-treated | 3 |
194 | 1,615 | 2 |
195 | 10,506 | 2 |
196 | 11,552 | 2 |
197 | 12,361 | 2 |
198 | 14,500 | 2 |
199 | 15,418 | 2 |
200 | 16/43 | 2 |
201 | 19,829 | 2 |
202 | 2,855 | 2 |
203 | 21,611 | 2 |
204 | 2t-responsive | 2 |
205 | 3,129 | 2 |
206 | 3,627 | 2 |
207 | 35,061 | 2 |
208 | 3978 | 2 |
209 | 4,035 | 2 |
210 | 4330 | 2 |
211 | 4360 | 2 |
212 | 4983 | 2 |
213 | 4992 | 2 |
214 | 5,078 | 2 |
215 | 5,234 | 2 |
216 | 5,683 | 2 |
217 | 5535 | 2 |
218 | 5728 | 2 |
219 | 5744 | 2 |
220 | 60-69-year-old | 2 |
221 | 6026 | 2 |
222 | 6039 | 2 |
223 | 7685 | 2 |
224 | 7814 | 2 |
225 | 8,582 | 2 |
226 | 9919 | 2 |
227 | american-indian | 2 |
228 | anejaculatory | 2 |
229 | as+cad | 2 |
230 | bcr/abl-positive | 2 |
231 | biomarker-selected | 2 |
232 | brb-responsive | 2 |
233 | carbenicillin-treated | 2 |
234 | chamaeleon | 2 |
235 | context.more | 2 |
236 | d425 | 2 |
237 | diuretic-treated | 2 |
238 | dr-dmf-treated | 2 |
239 | er-α-negative | 2 |
240 | fibrinolytic-eligible | 2 |
241 | gly16/glu27 | 2 |
242 | immunosupressed | 2 |
243 | iugr/aredv | 2 |
244 | low-education | 2 |
245 | low-intake | 2 |
246 | low-literate | 2 |
247 | low-to-moderate-demand | 2 |
248 | ma-abusing | 2 |
249 | medical/obstetrical | 2 |
250 | mixed-risk | 2 |
251 | moxonidine-treated | 2 |
252 | mtx-refractory | 2 |
253 | myoblast-treated | 2 |
254 | non-aian | 2 |
255 | non-court-referred | 2 |
256 | non-drug-using | 2 |
257 | non-incentivized | 2 |
258 | non-sportive | 2 |
259 | nonapathic | 2 |
260 | nondigitalized | 2 |
261 | nonimpaired | 2 |
262 | om-treated | 2 |
263 | omt-only | 2 |
264 | pd-treated | 2 |
265 | pi-experienced | 2 |
266 | polychemotherapy-related | 2 |
267 | post-adolescent | 2 |
268 | pr-negative | 2 |
269 | prion-exposed | 2 |
270 | psychostimulant-dependent | 2 |
271 | rf-negative | 2 |
272 | rnmb-present | 2 |
273 | slnb-positive | 2 |
274 | split-brain | 2 |
275 | t3-4n0-1 | 2 |
276 | vaccine-relevant | 2 |
277 | wart-associated | 2 |
278 | wart-related | 2 |
279 | well-phenotyped | 2 |
280 | ~20,000 | 2 |
281 | 1,199,057 | 1 |
282 | 10,071 | 1 |
283 | 1000000 | 1 |
284 | 1153/97,445 | 1 |
285 | 15,330 | 1 |
286 | 16,448 | 1 |
287 | 19,857 | 1 |
288 | 2,810 | 1 |
289 | 274,518 | 1 |
290 | 3-t-guided | 1 |
291 | 31010 | 1 |
292 | 34,705 | 1 |
293 | 356,196 | 1 |
294 | 40,530 | 1 |
295 | 41,213 | 1 |
296 | 42-mg-ba | 1 |
297 | 47,382 | 1 |
298 | 5,644 | 1 |
299 | 533-mug | 1 |
300 | 54,611 | 1 |
301 | 5670 | 1 |
302 | 6,281 | 1 |
303 | 6,735 | 1 |
304 | 6098 | 1 |
305 | 65,769 | 1 |
306 | 73,675 | 1 |
307 | 74098 | 1 |
308 | 77,633 | 1 |
309 | 8878 | 1 |
310 | 96/134 | 1 |
311 | afp-producing | 1 |
312 | all-coming | 1 |
313 | alpha-9 | 1 |
314 | analysis.seventy-six | 1 |
315 | anti-recoverin-positive | 1 |
316 | aproper | 1 |
317 | arteryesnendovascular | 1 |
318 | asc-us/high-risk | 1 |
319 | asst.the | 1 |
320 | atypical-treated | 1 |
321 | barbus | 1 |
322 | bikaneri | 1 |
323 | brahman-influenced | 1 |
324 | bu-resistant | 1 |
325 | cam-positive | 1 |
326 | camburi | 1 |
327 | cannabis-abusing | 1 |
328 | cystinuric | 1 |
329 | dengue-naïve | 1 |
330 | dha-pretreated | 1 |
331 | dsg-naïve | 1 |
332 | european-derived | 1 |
333 | european-origin | 1 |
334 | f4/80high | 1 |
335 | flood-affected | 1 |
336 | genetically-proven | 1 |
337 | gonadotropin-suppressed | 1 |
338 | good-performance | 1 |
339 | gtl-16 | 1 |
340 | gts-related | 1 |
341 | hbv-transfected | 1 |
342 | hd/pd | 1 |
343 | hsv-exposed | 1 |
344 | idalopirdine-treated | 1 |
345 | initial/persistent | 1 |
346 | intergrading | 1 |
347 | intervention-appropriate | 1 |
348 | lasik-treated | 1 |
349 | less-selected | 1 |
350 | leukotriene-responsiveness | 1 |
351 | ls/ss | 1 |
352 | match-adjusted | 1 |
353 | methamphetamine-injecting | 1 |
354 | mtrx1011a-treated | 1 |
355 | multiple-strain | 1 |
356 | mutation-defined | 1 |
357 | my09/my11/hmb01 | 1 |
358 | negative/low-risk | 1 |
359 | network-structured | 1 |
360 | non-prehypertensive | 1 |
361 | non-seroprotected | 1 |
362 | non-ucd | 1 |
363 | non-vaccine-associated | 1 |
364 | nonepilepsy | 1 |
365 | nonneuropsychiatric | 1 |
366 | nrti-naive | 1 |
367 | odn-treating | 1 |
368 | out-of-africa | 1 |
369 | populations.in | 1 |
370 | quatre | 1 |
371 | rct-ineligible | 1 |
372 | refuser | 1 |
373 | resource-stressed | 1 |
374 | sidama | 1 |
375 | situations-which | 1 |
376 | slfn3-null | 1 |
377 | standard-dose-resistant | 1 |
378 | statin-responsive | 1 |
379 | stich-like | 1 |
380 | t790/st22 | 1 |
381 | target-bearing | 1 |
382 | target-selected | 1 |
383 | th-treated | 1 |
384 | thermally-tolerant | 1 |
385 | thiazolidinedione-treated | 1 |
386 | tipranavir-treated | 1 |
387 | trpv2-expressing | 1 |
388 | unknown-risk | 1 |
389 | vitro-predicted | 1 |
390 | x-irradiated | 1 |
391 | y16f-mutant | 1 |
392 | zebu-derived | 1 |
1 | 1,199,057 | 1 |
2 | 1,615 | 2 |
3 | 10,071 | 1 |
4 | 10,506 | 2 |
5 | 1000000 | 1 |
6 | 11,552 | 2 |
7 | 1153/97,445 | 1 |
8 | 12,361 | 2 |
9 | 14,090 | 3 |
10 | 14,500 | 2 |
11 | 14,776 | 3 |
12 | 15,330 | 1 |
13 | 15,418 | 2 |
14 | 16,448 | 1 |
15 | 16/43 | 2 |
16 | 19,829 | 2 |
17 | 19,857 | 1 |
18 | 2,036 | 4 |
19 | 2,518 | 5 |
20 | 2,627 | 7 |
21 | 2,810 | 1 |
22 | 2,855 | 2 |
23 | 2,974 | 4 |
24 | 21,611 | 2 |
25 | 2312 | 6 |
26 | 25,104 | 3 |
27 | 2706 | 6 |
28 | 274,518 | 1 |
29 | 2827 | 4 |
30 | 2984 | 4 |
31 | 2t-responsive | 2 |
32 | 3,129 | 2 |
33 | 3,627 | 2 |
34 | 3-t-guided | 1 |
35 | 31010 | 1 |
36 | 3180 | 7 |
37 | 3334 | 3 |
38 | 34,705 | 1 |
39 | 35,061 | 2 |
40 | 356,196 | 1 |
41 | 3978 | 2 |
42 | 4,035 | 2 |
43 | 4,137 | 3 |
44 | 4,295 | 3 |
45 | 40,530 | 1 |
46 | 4035 | 4 |
47 | 41,213 | 1 |
48 | 42-mg-ba | 1 |
49 | 4237 | 8 |
50 | 4282 | 4 |
51 | 4330 | 2 |
52 | 4360 | 2 |
53 | 47,382 | 1 |
54 | 4718 | 5 |
55 | 4983 | 2 |
56 | 4992 | 2 |
57 | 5,078 | 2 |
58 | 5,234 | 2 |
59 | 5,644 | 1 |
60 | 5,683 | 2 |
61 | 5,733 | 3 |
62 | 533-mug | 1 |
63 | 54,611 | 1 |
64 | 5535 | 2 |
65 | 5670 | 1 |
66 | 5728 | 2 |
67 | 5744 | 2 |
68 | 6,281 | 1 |
69 | 6,380 | 3 |
70 | 6,735 | 1 |
71 | 60-69-year-old | 2 |
72 | 6026 | 2 |
73 | 6039 | 2 |
74 | 6098 | 1 |
75 | 65,769 | 1 |
76 | 73,675 | 1 |
77 | 74098 | 1 |
78 | 7685 | 2 |
79 | 77,633 | 1 |
80 | 7814 | 2 |
81 | 8,582 | 2 |
82 | 8351 | 4 |
83 | 8878 | 1 |
84 | 96/134 | 1 |
85 | 9919 | 2 |
86 | acidilobus-like | 3 |
87 | acute-mi | 3 |
88 | added-risk | 3 |
89 | adverse-risk | 4 |
90 | afp-producing | 1 |
91 | alcohol-responsive | 3 |
92 | all-comer | 40 |
93 | all-coming | 1 |
94 | alloimmunized | 19 |
95 | alpha-9 | 1 |
96 | american-indian | 2 |
97 | analysis.seventy-six | 1 |
98 | anejaculatory | 2 |
99 | anti-ccp-negative | 3 |
100 | anti-recoverin-positive | 1 |
101 | any-type | 3 |
102 | aproper | 1 |
103 | arteryesnendovascular | 1 |
104 | as+cad | 2 |
105 | asc-us/high-risk | 1 |
106 | asst.the | 1 |
107 | at-risk | 1,143 |
108 | atypical-treated | 1 |
109 | average-risk | 90 |
110 | b-infected | 10 |
111 | barbus | 1 |
112 | bcr/abl-positive | 2 |
113 | bikaneri | 1 |
114 | biomarker-defined | 6 |
115 | biomarker-negative | 14 |
116 | biomarker-selected | 2 |
117 | brahman-influenced | 1 |
118 | brb-responsive | 2 |
119 | brca-mutated | 5 |
120 | bu-resistant | 1 |
121 | c-infected | 8 |
122 | cam-positive | 1 |
123 | camburi | 1 |
124 | cancer-prone | 6 |
125 | cannabis-abusing | 1 |
126 | carbenicillin-treated | 2 |
127 | chamaeleon | 2 |
128 | chemotherapy-treated | 20 |
129 | cmv-antibody-negative | 3 |
130 | cns-negative | 3 |
131 | co-trimoxazole-treated | 3 |
132 | conservatively-treated | 7 |
133 | context.more | 2 |
134 | cystinuric | 1 |
135 | d425 | 2 |
136 | delayed-arm | 4 |
137 | dengue-naïve | 1 |
138 | dha-pretreated | 1 |
139 | difficult-to-engage | 3 |
140 | difficult-to-treat | 145 |
141 | difluprednate-treated | 8 |
142 | diuretic-treated | 2 |
143 | dm1-affected | 3 |
144 | doctor-shopping | 5 |
145 | dr-dmf-treated | 2 |
146 | dsg-naïve | 1 |
147 | dually-diagnosed | 3 |
148 | ei-aed | 3 |
149 | er-negative/her2-negative | 3 |
150 | er-α-negative | 2 |
151 | esomeprazole-treated | 5 |
152 | european-derived | 1 |
153 | european-origin | 1 |
154 | f4/80high | 1 |
155 | feeble-minded | 3 |
156 | fibrinolytic-eligible | 2 |
157 | fibrinolytic-treated | 7 |
158 | fish-negative | 6 |
159 | flood-affected | 1 |
160 | gastric-cardia | 4 |
161 | gata-3-negative | 4 |
162 | general-risk | 3 |
163 | genetically-proven | 1 |
164 | genotype-negative | 5 |
165 | gerontal | 3 |
166 | gly16/glu27 | 2 |
167 | gnrha-treated | 3 |
168 | gonadotropin-suppressed | 1 |
169 | good-grade | 6 |
170 | good-performance | 1 |
171 | good-risk | 30 |
172 | gord-negative | 5 |
173 | gstt1-null | 3 |
174 | gtl-16 | 1 |
175 | gts-related | 1 |
176 | hard-to-reach | 25 |
177 | hard-to-treat | 9 |
178 | hbv-transfected | 1 |
179 | hd/pd | 1 |
180 | high-barriers | 3 |
181 | high-caries-risk | 5 |
182 | high-complexity | 7 |
183 | high-coverage | 4 |
184 | high-cvd-risk | 5 |
185 | high-intermediate-risk | 5 |
186 | high-need | 5 |
187 | high-risk | 8,704 |
188 | high-surgical-risk | 5 |
189 | high-tension | 5 |
190 | higher-risk | 186 |
191 | highly-selected | 4 |
192 | highrisk | 9 |
193 | hm100 | 3 |
194 | home-bound | 3 |
195 | hpv-naïve | 5 |
196 | hsv-exposed | 1 |
197 | idalopirdine-treated | 1 |
198 | immunoresponsive | 3 |
199 | immunosupressed | 2 |
200 | in-tunnel | 4 |
201 | initial/persistent | 1 |
202 | intensive-lifestyle | 4 |
203 | intergrading | 1 |
204 | intermediate-risk | 269 |
205 | intermediate/high-risk | 4 |
206 | intervention-appropriate | 1 |
207 | iugr/aredv | 2 |
208 | jupiter-eligible | 5 |
209 | lasik-treated | 1 |
210 | lavender-thymol-treated | 4 |
211 | less-active | 5 |
212 | less-selected | 1 |
213 | leukotriene-responsiveness | 1 |
214 | low-complexity | 8 |
215 | low-education | 2 |
216 | low-intake | 2 |
217 | low-literate | 2 |
218 | low-risk | 1,549 |
219 | low-to-moderate-demand | 2 |
220 | low-weight | 23 |
221 | lower-risk | 104 |
222 | ls/ss | 1 |
223 | lung-healthy | 4 |
224 | ma-abusing | 2 |
225 | match-adjusted | 1 |
226 | media-recruited | 3 |
227 | medical/obstetrical | 2 |
228 | medication-treated | 7 |
229 | medium-risk | 31 |
230 | met-positive | 11 |
231 | methamphetamine-injecting | 1 |
232 | methotrexate-refractory | 7 |
233 | mixed-risk | 2 |
234 | moderate-risk | 77 |
235 | moderate/high-risk | 5 |
236 | moxonidine-treated | 2 |
237 | mtrx1011a-treated | 1 |
238 | mtx-refractory | 2 |
239 | mtx-resistant | 5 |
240 | multi-problem | 3 |
241 | multiple-strain | 1 |
242 | mupirocin-treated | 11 |
243 | mutation-defined | 1 |
244 | my09/my11/hmb01 | 1 |
245 | myoblast-treated | 2 |
246 | negative/low-risk | 1 |
247 | network-structured | 1 |
248 | no-option | 19 |
249 | non-16 | 5 |
250 | non-aian | 2 |
251 | non-art | 24 |
252 | non-bleeding | 22 |
253 | non-bloom | 3 |
254 | non-breastfeeding | 16 |
255 | non-converted | 4 |
256 | non-court-referred | 2 |
257 | non-drug-using | 2 |
258 | non-educated | 3 |
259 | non-fn | 20 |
260 | non-gca | 6 |
261 | non-hc2-targeted | 3 |
262 | non-high-risk | 31 |
263 | non-ibd | 9 |
264 | non-incentivized | 2 |
265 | non-low-risk | 3 |
266 | non-pad | 4 |
267 | non-pneumonic | 5 |
268 | non-prehypertensive | 1 |
269 | non-ptdm | 3 |
270 | non-renal | 46 |
271 | non-risk | 11 |
272 | non-sci | 3 |
273 | non-selected | 40 |
274 | non-seroprotected | 1 |
275 | non-sportive | 2 |
276 | non-trial | 35 |
277 | non-typical | 4 |
278 | non-ucd | 1 |
279 | non-vaccine-associated | 1 |
280 | non-varus | 3 |
281 | non-young | 6 |
282 | nonapathic | 2 |
283 | nonbleeding | 14 |
284 | nondigitalized | 2 |
285 | nonenrolled | 15 |
286 | nonepilepsy | 1 |
287 | nonfluctuating | 7 |
288 | nonimpaired | 2 |
289 | nonintervened | 4 |
290 | nonneuropsychiatric | 1 |
291 | nonreferred | 5 |
292 | nonreperfused | 10 |
293 | nonsedated | 9 |
294 | nonselected | 38 |
295 | nontransplant | 35 |
296 | nontrial | 45 |
297 | nonuremic | 14 |
298 | nonventilated | 19 |
299 | nrti-naive | 1 |
300 | odn-treating | 1 |
301 | om-treated | 2 |
302 | omt-only | 2 |
303 | out-of-africa | 1 |
304 | out-of-treatment | 17 |
305 | out-trial | 4 |
306 | overnight-stay | 5 |
307 | pci-treated | 32 |
308 | pd-treated | 2 |
309 | photon-treated | 4 |
310 | pi-experienced | 2 |
311 | platinum-pretreated | 6 |
312 | polychemotherapy-related | 2 |
313 | polymorbid | 4 |
314 | polytraumatized | 5 |
315 | poor-outcome | 3 |
316 | poor-prognosis | 48 |
317 | poor-risk | 76 |
318 | populations.in | 1 |
319 | post-adolescent | 2 |
320 | ppci-treated | 5 |
321 | pr-negative | 2 |
322 | pre-orthodontic | 3 |
323 | pre-symptomatic | 26 |
324 | prion-exposed | 2 |
325 | psychostimulant-dependent | 2 |
326 | ptsd+ | 8 |
327 | quatre | 1 |
328 | ranibizumab-treated | 42 |
329 | rct-ineligible | 1 |
330 | refuser | 1 |
331 | remifentanil-treated | 5 |
332 | resource-stressed | 1 |
333 | rf-negative | 2 |
334 | risk-stratifying | 10 |
335 | rituximab-refractory | 15 |
336 | rnmb-present | 2 |
337 | roxithromycin-treated | 4 |
338 | screening-eligible | 4 |
339 | secure-c | 8 |
340 | selenium-replete | 3 |
341 | sidama | 1 |
342 | sitosterolemic | 6 |
343 | situations-which | 1 |
344 | slfn3-null | 1 |
345 | slnb-positive | 2 |
346 | slow-progressing | 3 |
347 | sodium-sensitive | 6 |
348 | split-brain | 2 |
349 | standard-dose-resistant | 1 |
350 | standard-risk | 57 |
351 | statin-responsive | 1 |
352 | stich-like | 1 |
353 | stimulant-exposed | 3 |
354 | substance-using | 28 |
355 | t3-4n0-1 | 2 |
356 | t790/st22 | 1 |
357 | target-bearing | 1 |
358 | target-selected | 1 |
359 | telavancin-treated | 3 |
360 | th-treated | 1 |
361 | thermally-tolerant | 1 |
362 | thiazolidinedione-treated | 1 |
363 | three-member | 4 |
364 | tipranavir-treated | 1 |
365 | tolvaptan-treated | 6 |
366 | transplantation-eligible | 3 |
367 | trpv2-expressing | 1 |
368 | ultra-early | 18 |
369 | ultra-high-risk | 13 |
370 | uncured | 14 |
371 | under-served | 8 |
372 | unknown-risk | 1 |
373 | unselected | 865 |
374 | vaccine-relevant | 2 |
375 | vasc+ | 3 |
376 | vegfr-tki-refractory | 3 |
377 | vemurafenib-treated | 3 |
378 | very-high-risk | 25 |
379 | vitro-predicted | 1 |
380 | wadam | 4 |
381 | wart-associated | 2 |
382 | wart-related | 2 |
383 | well-infant | 4 |
384 | well-phenotyped | 2 |
385 | well-selected | 39 |
386 | well-treated | 10 |
387 | wide-type | 4 |
388 | x-irradiated | 1 |
389 | y16f-mutant | 1 |
390 | zebu-derived | 1 |
391 | ~20,000 | 2 |
392 | β3t-positive | 4 |
1 | vasc+ | 3 |
2 | ptsd+ | 8 |
3 | ~20,000 | 2 |
4 | 1000000 | 1 |
5 | hm100 | 3 |
6 | 14,500 | 2 |
7 | 31010 | 1 |
8 | 2,810 | 1 |
9 | 15,330 | 1 |
10 | 4330 | 2 |
11 | 40,530 | 1 |
12 | 4360 | 2 |
13 | 5670 | 1 |
14 | 3180 | 7 |
15 | 6,380 | 3 |
16 | 14,090 | 3 |
17 | t3-4n0-1 | 2 |
18 | my09/my11/hmb01 | 1 |
19 | 21,611 | 2 |
20 | 54,611 | 1 |
21 | 8351 | 4 |
22 | 35,061 | 2 |
23 | 12,361 | 2 |
24 | 10,071 | 1 |
25 | 6,281 | 1 |
26 | 2312 | 6 |
27 | t790/st22 | 1 |
28 | 11,552 | 2 |
29 | 4282 | 4 |
30 | 47,382 | 1 |
31 | 8,582 | 2 |
32 | 4992 | 2 |
33 | 41,213 | 1 |
34 | 77,633 | 1 |
35 | 5,733 | 3 |
36 | 16/43 | 2 |
37 | 5,683 | 2 |
38 | 4983 | 2 |
39 | 25,104 | 3 |
40 | 7814 | 2 |
41 | 96/134 | 1 |
42 | 5,234 | 2 |
43 | 3334 | 3 |
44 | 5,644 | 1 |
45 | 5744 | 2 |
46 | 2,974 | 4 |
47 | 2984 | 4 |
48 | 34,705 | 1 |
49 | 1,615 | 2 |
50 | d425 | 2 |
51 | 4,035 | 2 |
52 | 4035 | 4 |
53 | 5535 | 2 |
54 | 6,735 | 1 |
55 | 1153/97,445 | 1 |
56 | 2,855 | 2 |
57 | 73,675 | 1 |
58 | 7685 | 2 |
59 | 4,295 | 3 |
60 | 10,506 | 2 |
61 | 2706 | 6 |
62 | gtl-16 | 1 |
63 | non-16 | 5 |
64 | 6026 | 2 |
65 | 2,036 | 4 |
66 | 14,776 | 3 |
67 | 356,196 | 1 |
68 | 2,627 | 7 |
69 | 3,627 | 2 |
70 | 2827 | 4 |
71 | gly16/glu27 | 2 |
72 | 4,137 | 3 |
73 | 4237 | 8 |
74 | 1,199,057 | 1 |
75 | 19,857 | 1 |
76 | 15,418 | 2 |
77 | 2,518 | 5 |
78 | 274,518 | 1 |
79 | 4718 | 5 |
80 | 5728 | 2 |
81 | 16,448 | 1 |
82 | 5,078 | 2 |
83 | 8878 | 1 |
84 | 3978 | 2 |
85 | 74098 | 1 |
86 | 6098 | 1 |
87 | alpha-9 | 1 |
88 | 9919 | 2 |
89 | 3,129 | 2 |
90 | 19,829 | 2 |
91 | 6039 | 2 |
92 | 65,769 | 1 |
93 | 42-mg-ba | 1 |
94 | non-gca | 6 |
95 | out-of-africa | 1 |
96 | gastric-cardia | 4 |
97 | sidama | 1 |
98 | secure-c | 8 |
99 | nonapathic | 2 |
100 | sitosterolemic | 6 |
101 | nonuremic | 14 |
102 | non-pneumonic | 5 |
103 | nonneuropsychiatric | 1 |
104 | cystinuric | 1 |
105 | pre-symptomatic | 26 |
106 | pre-orthodontic | 3 |
107 | as+cad | 2 |
108 | non-pad | 4 |
109 | non-ibd | 9 |
110 | non-ucd | 1 |
111 | ei-aed | 3 |
112 | pi-experienced | 2 |
113 | brahman-influenced | 1 |
114 | 3-t-guided | 1 |
115 | feeble-minded | 3 |
116 | high-need | 5 |
117 | nonenrolled | 15 |
118 | nonintervened | 4 |
119 | mutation-defined | 1 |
120 | biomarker-defined | 6 |
121 | well-phenotyped | 2 |
122 | nonimpaired | 2 |
123 | non-court-referred | 2 |
124 | nonreferred | 5 |
125 | uncured | 14 |
126 | network-structured | 1 |
127 | dually-diagnosed | 3 |
128 | prion-exposed | 2 |
129 | stimulant-exposed | 3 |
130 | hsv-exposed | 1 |
131 | gonadotropin-suppressed | 1 |
132 | immunosupressed | 2 |
133 | resource-stressed | 1 |
134 | nonreperfused | 10 |
135 | non-educated | 3 |
136 | nonsedated | 9 |
137 | mtrx1011a-treated | 1 |
138 | gnrha-treated | 3 |
139 | ranibizumab-treated | 42 |
140 | vemurafenib-treated | 3 |
141 | diuretic-treated | 2 |
142 | fibrinolytic-treated | 7 |
143 | pd-treated | 2 |
144 | esomeprazole-treated | 5 |
145 | co-trimoxazole-treated | 3 |
146 | moxonidine-treated | 2 |
147 | idalopirdine-treated | 1 |
148 | thiazolidinedione-treated | 1 |
149 | difluprednate-treated | 8 |
150 | dr-dmf-treated | 2 |
151 | th-treated | 1 |
152 | pci-treated | 32 |
153 | ppci-treated | 5 |
154 | lasik-treated | 1 |
155 | atypical-treated | 1 |
156 | remifentanil-treated | 5 |
157 | well-treated | 10 |
158 | lavender-thymol-treated | 4 |
159 | om-treated | 2 |
160 | tolvaptan-treated | 6 |
161 | telavancin-treated | 3 |
162 | mupirocin-treated | 11 |
163 | roxithromycin-treated | 4 |
164 | carbenicillin-treated | 2 |
165 | medication-treated | 7 |
166 | photon-treated | 4 |
167 | tipranavir-treated | 1 |
168 | myoblast-treated | 2 |
169 | conservatively-treated | 7 |
170 | chemotherapy-treated | 20 |
171 | dha-pretreated | 1 |
172 | platinum-pretreated | 6 |
173 | non-vaccine-associated | 1 |
174 | wart-associated | 2 |
175 | x-irradiated | 1 |
176 | gts-related | 1 |
177 | wart-related | 2 |
178 | polychemotherapy-related | 2 |
179 | nonventilated | 19 |
180 | brca-mutated | 5 |
181 | dm1-affected | 3 |
182 | flood-affected | 1 |
183 | b-infected | 10 |
184 | c-infected | 8 |
185 | hbv-transfected | 1 |
186 | well-selected | 39 |
187 | non-selected | 40 |
188 | biomarker-selected | 2 |
189 | less-selected | 1 |
190 | target-selected | 1 |
191 | highly-selected | 4 |
192 | nonselected | 38 |
193 | unselected | 865 |
194 | non-seroprotected | 1 |
195 | vitro-predicted | 1 |
196 | non-hc2-targeted | 3 |
197 | media-recruited | 3 |
198 | non-converted | 4 |
199 | match-adjusted | 1 |
200 | european-derived | 1 |
201 | zebu-derived | 1 |
202 | under-served | 8 |
203 | nondigitalized | 2 |
204 | alloimmunized | 19 |
205 | polytraumatized | 5 |
206 | non-incentivized | 2 |
207 | polymorbid | 4 |
208 | 60-69-year-old | 2 |
209 | low-to-moderate-demand | 2 |
210 | home-bound | 3 |
211 | hd/pd | 1 |
212 | good-performance | 1 |
213 | good-grade | 6 |
214 | difficult-to-engage | 3 |
215 | high-coverage | 4 |
216 | asst.the | 1 |
217 | low-intake | 2 |
218 | stich-like | 1 |
219 | acidilobus-like | 3 |
220 | fibrinolytic-eligible | 2 |
221 | screening-eligible | 4 |
222 | transplantation-eligible | 3 |
223 | jupiter-eligible | 5 |
224 | rct-ineligible | 1 |
225 | intensive-lifestyle | 4 |
226 | poor-outcome | 3 |
227 | cancer-prone | 6 |
228 | wide-type | 4 |
229 | any-type | 3 |
230 | context.more | 2 |
231 | quatre | 1 |
232 | intervention-appropriate | 1 |
233 | low-literate | 2 |
234 | selenium-replete | 3 |
235 | nrti-naive | 1 |
236 | non-prehypertensive | 1 |
237 | brb-responsive | 2 |
238 | alcohol-responsive | 3 |
239 | statin-responsive | 1 |
240 | 2t-responsive | 2 |
241 | immunoresponsive | 3 |
242 | er-negative/her2-negative | 3 |
243 | gata-3-negative | 4 |
244 | gord-negative | 5 |
245 | genotype-negative | 5 |
246 | rf-negative | 2 |
247 | fish-negative | 6 |
248 | anti-ccp-negative | 3 |
249 | biomarker-negative | 14 |
250 | pr-negative | 2 |
251 | cns-negative | 3 |
252 | cmv-antibody-negative | 3 |
253 | er-α-negative | 2 |
254 | less-active | 5 |
255 | sodium-sensitive | 6 |
256 | slnb-positive | 2 |
257 | bcr/abl-positive | 2 |
258 | cam-positive | 1 |
259 | anti-recoverin-positive | 1 |
260 | β3t-positive | 4 |
261 | met-positive | 11 |
262 | non-sportive | 2 |
263 | dengue-naïve | 1 |
264 | dsg-naïve | 1 |
265 | hpv-naïve | 5 |
266 | afp-producing | 1 |
267 | intergrading | 1 |
268 | non-breastfeeding | 16 |
269 | non-bleeding | 22 |
270 | nonbleeding | 14 |
271 | all-coming | 1 |
272 | doctor-shopping | 5 |
273 | target-bearing | 1 |
274 | slow-progressing | 3 |
275 | trpv2-expressing | 1 |
276 | substance-using | 28 |
277 | non-drug-using | 2 |
278 | ma-abusing | 2 |
279 | cannabis-abusing | 1 |
280 | odn-treating | 1 |
281 | nonfluctuating | 7 |
282 | methamphetamine-injecting | 1 |
283 | risk-stratifying | 10 |
284 | non-young | 6 |
285 | 533-mug | 1 |
286 | hard-to-reach | 25 |
287 | situations-which | 1 |
288 | f4/80high | 1 |
289 | non-sci | 3 |
290 | acute-mi | 3 |
291 | bikaneri | 1 |
292 | camburi | 1 |
293 | added-risk | 3 |
294 | mixed-risk | 2 |
295 | good-risk | 30 |
296 | standard-risk | 57 |
297 | high-cvd-risk | 5 |
298 | average-risk | 90 |
299 | adverse-risk | 4 |
300 | intermediate-risk | 269 |
301 | high-intermediate-risk | 5 |
302 | moderate-risk | 77 |
303 | high-risk | 8,704 |
304 | ultra-high-risk | 13 |
305 | non-high-risk | 31 |
306 | very-high-risk | 25 |
307 | intermediate/high-risk | 4 |
308 | moderate/high-risk | 5 |
309 | asc-us/high-risk | 1 |
310 | high-surgical-risk | 5 |
311 | general-risk | 3 |
312 | medium-risk | 31 |
313 | non-risk | 11 |
314 | unknown-risk | 1 |
315 | higher-risk | 186 |
316 | lower-risk | 104 |
317 | poor-risk | 76 |
318 | high-caries-risk | 5 |
319 | at-risk | 1,143 |
320 | low-risk | 1,549 |
321 | non-low-risk | 3 |
322 | negative/low-risk | 1 |
323 | highrisk | 9 |
324 | non-typical | 4 |
325 | medical/obstetrical | 2 |
326 | non-trial | 35 |
327 | out-trial | 4 |
328 | nontrial | 45 |
329 | non-renal | 46 |
330 | gerontal | 3 |
331 | in-tunnel | 4 |
332 | gstt1-null | 3 |
333 | slfn3-null | 1 |
334 | wadam | 4 |
335 | non-ptdm | 3 |
336 | multi-problem | 3 |
337 | non-bloom | 3 |
338 | delayed-arm | 4 |
339 | non-aian | 2 |
340 | american-indian | 2 |
341 | genetically-proven | 1 |
342 | non-fn | 20 |
343 | populations.in | 1 |
344 | split-brain | 2 |
345 | multiple-strain | 1 |
346 | european-origin | 1 |
347 | chamaeleon | 2 |
348 | high-tension | 5 |
349 | low-education | 2 |
350 | no-option | 19 |
351 | arteryesnendovascular | 1 |
352 | three-member | 4 |
353 | all-comer | 40 |
354 | aproper | 1 |
355 | refuser | 1 |
356 | poor-prognosis | 48 |
357 | high-barriers | 3 |
358 | ls/ss | 1 |
359 | leukotriene-responsiveness | 1 |
360 | barbus | 1 |
361 | non-varus | 3 |
362 | hard-to-treat | 9 |
363 | difficult-to-treat | 145 |
364 | low-weight | 23 |
365 | well-infant | 4 |
366 | nontransplant | 35 |
367 | thermally-tolerant | 1 |
368 | standard-dose-resistant | 1 |
369 | bu-resistant | 1 |
370 | mtx-resistant | 5 |
371 | y16f-mutant | 1 |
372 | vaccine-relevant | 2 |
373 | post-adolescent | 2 |
374 | psychostimulant-dependent | 2 |
375 | out-of-treatment | 17 |
376 | rnmb-present | 2 |
377 | initial/persistent | 1 |
378 | non-art | 24 |
379 | iugr/aredv | 2 |
380 | analysis.seventy-six | 1 |
381 | overnight-stay | 5 |
382 | lung-healthy | 4 |
383 | omt-only | 2 |
384 | ultra-early | 18 |
385 | anejaculatory | 2 |
386 | rituximab-refractory | 15 |
387 | methotrexate-refractory | 7 |
388 | vegfr-tki-refractory | 3 |
389 | mtx-refractory | 2 |
390 | nonepilepsy | 1 |
391 | high-complexity | 7 |
392 | low-complexity | 8 |